Acyclovir-d4(Synonyms: Aciclovir-d4; Acycloguanosine-d4)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Acyclovir-d4 (Synonyms: Aciclovir-d4; Acycloguanosine-d4)

Acyclovir-d4 (Aciclovir-d4) 是 Acyclovir 的氘代物。Acyclovir (Aciclovir) 是一种鸟嘌呤类似物和一种具有口服活性的抗病毒剂。Acyclovir 具有抗 HSV-1 (IC50 为 0.85 μM)，HSV-2 (IC50 为 0.86 μM) 和水痘带状疱疹病毒的活性。Acyclovir 可被病毒胸苷激酶 (TK) 磷酸化，Acyclovir triphosphate 可干扰病毒 DNA 聚合。Acyclovir 可预防急性白血病的诱导疗法中的细菌感染。

Acyclovir-d4(Synonyms: Aciclovir-d4; Acycloguanosine-d4)

Acyclovir-d4 Chemical Structure

CAS No. : 1185179-33-2

规格 价格 是否有货
1 mg ￥3500 询问价格 & 货期
5 mg ￥14000 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Acyclovir-d4 (Aciclovir-d4) is the deuterium labeled Acyclovir. Acyclovir (Aciclovir) is a guanosine analogue and an orally active antiviral agent. Acyclovir inhibits HSV-1 (IC50 of 0.85 μM), HSV-2 (IC50 of 0.86 μM) and varicella-zoster virus. Acyclovir can be phosphorylated by viral thymidine kinase (TK), and Acyclovir triphosphate interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate and obligatory chain termination[1][2][3]. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia[4].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

229.23

Formula

C8H7D4N5O3
CAS 号

1185179-33-2
中文名称

阿昔洛韦 d4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Li Z, et al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10(5):251-7.

    [3]. Suzuki M, et al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61.

    [4]. Benedetti S, et al. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. Life Sci. 2018 Dec 15;215:80-85.

    [5]. Hayashi K, et al. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy. J Gene Med. 2006 Aug;8(8):1056-67.

    [6]. Lönnqvist B, et al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1(3):139-44.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务